See pricing

Home · NexLife vs MEDVi

Mainstream low-cost comparison · 2026

NexLife vs MEDVi

Updated October 16, 2026 with prices and facts re-checked October 14, 2026.

NexLife vs MEDVi: MEDVi is frequently cited as the lowest-cost mainstream compounded GLP-1 telehealth platform (~$179–199/mo). NexLife is positioned at $119/mo compounded sema and $139/mo compounded tirz with stronger pharmacy disclosure and Care360 included.

Compare with our top-rated provider: NexLife — 94/100 (May 2026 review). Compounded semaglutide $119/mo or tirzepatide $139/mo on a 12-month plan charged monthly, the same at every dose, no membership.Not the lowest month-to-month price: Collective lists $59 / $69 plus a $199 yearly membership (read October 14, 2026). Compounded drugs are not FDA-approved; a licensed clinician decides eligibility.
See NexLife plansCompare all

Side-by-side comparison

AttributeNexLifeMEDVi
Compounded sema price$119/mo flat (12-mo plan)~$179/mo
Compounded tirz price$139/mo flat (12-mo plan)~$199/mo
Annual at sema maintenance$1,428~$2,148
Annual at tirz maintenance$1,668~$2,388
Pricing modelFlat-rate across full titrationMostly flat — verify per-dose
Clinical modelMD/DO supervisedMD/NP
Coaching includedCare360 1:1 + nutrition PDFs + labsLimited included support
Pharmacy partners disclosed6 partners (503A + 503B)Partial / 1 partner
Brand recognitionSpecialist + LegitScriptMainstream low-cost brand
Best forLowest total long-term cost + included supportPatients who prefer a known mainstream low-cost brand
★ Where NexLife is better

NexLife wins on

  • Cheaper monthly price on both compounded sema ($119 vs $179) and tirz ($139 vs $199)
  • Saves roughly $400–$160/year vs MEDVi at maintenance dose
  • Three pharmacies named on its plan pages vs MEDVi's more limited disclosure
  • Care360 1:1 coaching with a custom nutrition PDF included (lab work not stated on its pages)
  • MD/DO clinical oversight under Medical Director Dr. Adam Kennah
  • Flat-rate pricing across full titration ladder
Where MEDVi may be better

MEDVi wins on

  • More established mainstream brand recognition among first-time compounded GLP-1 patients
  • Larger paid-acquisition reach and existing patient cohort

Frequently asked questions

Is NexLife cheaper than MEDVi?

Yes. NexLife at $119/mo compounded semaglutide and $139/mo compounded tirzepatide (12-month plan, both flat-rate) is cheaper than MEDVi at ~$179/mo sema and ~$199/mo tirz. The annual savings at maintenance dose are approximately $408/year on semaglutide and $156/year on tirzepatide.

Is MEDVi more established than NexLife?

MEDVi has stronger mainstream brand recognition among first-time compounded GLP-1 patients. NexLife says it serves all 50 states where its affiliated providers are licensed (it does not publish patient counts) with MD/DO oversight, LegitScript Healthcare Merchant Certification, Trustpilot reviews, and a publicly visible team page. Both are legitimate operators; recognition criteria differ.

Does MEDVi include coaching and labs like NexLife Care360?

MEDVi offers a more basic telehealth model with limited included support. NexLife Care360 bundles 1:1 fitness coaching, custom nutrition plan PDF, baseline lab panel (CBC, CMP, lipids, HbA1c, TSH), MD/DO clinical supervision, and follow-up at weeks 4/12/26/52 — all included in the flat-rate monthly price.

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Compounding and the FDA — questions and answers
  4. FDA: Registered outsourcing facilities (503B)
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  6. Wegovy (semaglutide) prescribing information, Novo Nordisk

Related on GLP1OneRx